ERS Genomics announced March 28 that the European Patent Office (EPO) intends to grant ERS Genomics co-founder Dr. Emmanuelle Charpentier, together with the University of California and University of Vienna, a patent with very broad claims covering the use of CRISPR-Cas9 technology for gene editing.
The claims EPO intends to grant are directed toward the widely used single-guide CRISPR-Cas9 gene editing system and cover uses in both cellular and non-cellular settings, including use in
All access premium subscription
This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.
Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)
Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.
SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx
TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx